Skip to main content
Top
Published in: Supportive Care in Cancer 5/2012

01-05-2012 | Short Communication

Exploring physical activity level in patients with thoracic cancer: implications for use as an outcome measure

Authors: Matthew Maddocks, Andrew Wilcock

Published in: Supportive Care in Cancer | Issue 5/2012

Login to get access

Abstract

Purpose

Cachexia is common in patients with thoracic cancer impairing physical function and quality of life. New approaches which target muscle tissue are emerging and activity monitors could provide an objective assessment of their effect on physical function. We have collated data from three studies involving the use of one such monitor in order to benchmark aspects of physical activity for patients with thoracic cancer, explore how these relate to physician-rated performance status, and consider the implications for future studies.

Methods

Patients with thoracic cancer and an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0–2 wore an ActivPAL™ monitor for 1 week. The mean time spent each day in a range of activities, e.g. standing or stepping, or their frequency, e.g. number of sit-to-stand transitions, steps taken, were calculated and compared according to ECOG PS.

Results

Data from 84 patients (54 male; mean (SD) age, 66 (9) years) were collated. Each day, patients spent a mean (SD) of 4.3 (2.0) h upright, completed 45 (17) sit-to-stand transitions and took 4,246 (2,983) steps. There was wide variation in each activity examined. All but the number of sit-to-stand transitions differed significantly between ECOG PS categories.

Conclusions

These data provide a detailed insight into how physical activity levels decline across the range of ECOG PS categories studied. The wide variation in physical activity within each ECOG PS category suggests that this scale may lack sufficient sensitivity to evaluate new cachexia treatments. Our data help to inform future work in this area.
Literature
1.
go back to reference Laviano A, Meguid MM, Inui A, Muscaritoli M, Rossi-Fanelli F (2005) Therapy insight: cancer anorexia–cachexia syndrome—when all you can eat is yourself. Nat Clin Pract Oncol 2:158–165PubMedCrossRef Laviano A, Meguid MM, Inui A, Muscaritoli M, Rossi-Fanelli F (2005) Therapy insight: cancer anorexia–cachexia syndrome—when all you can eat is yourself. Nat Clin Pract Oncol 2:158–165PubMedCrossRef
3.
go back to reference Dodson S, Baracos VE, Jatoi A, Evans WJ, Cella D, Dalton JT, Steiner MS (2011) Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Ann Rev Med 62:265–279PubMedCrossRef Dodson S, Baracos VE, Jatoi A, Evans WJ, Cella D, Dalton JT, Steiner MS (2011) Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Ann Rev Med 62:265–279PubMedCrossRef
4.
go back to reference Mantovani G, Madeddu C, Serpe R (2010) Improvement of physical activity as an alternative objective variable to measure treatment effects of anti-cachexia therapy in cancer patients. Curr Opin Supp Pall Care 4(4):259–265CrossRef Mantovani G, Madeddu C, Serpe R (2010) Improvement of physical activity as an alternative objective variable to measure treatment effects of anti-cachexia therapy in cancer patients. Curr Opin Supp Pall Care 4(4):259–265CrossRef
5.
go back to reference Fearon KCH (2008) Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer 44:1124–1132PubMedCrossRef Fearon KCH (2008) Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer 44:1124–1132PubMedCrossRef
6.
go back to reference Maddocks M, Byrne A, Johnson CD, Wilson RH, Fearon KCH, Wilcock A (2009) Physical activity level as an outcome measure for use in cancer cachexia trials: a feasibility study. Supp Care Cancer 18:1539–1544CrossRef Maddocks M, Byrne A, Johnson CD, Wilson RH, Fearon KCH, Wilcock A (2009) Physical activity level as an outcome measure for use in cancer cachexia trials: a feasibility study. Supp Care Cancer 18:1539–1544CrossRef
7.
go back to reference Grant PM, Ryan CG, Tigbe WW, Granat MH (2006) The validation of a novel activity monitor in the measurement of posture and motion during everyday activities. Br J Sports Med 40:992–997PubMedCrossRef Grant PM, Ryan CG, Tigbe WW, Granat MH (2006) The validation of a novel activity monitor in the measurement of posture and motion during everyday activities. Br J Sports Med 40:992–997PubMedCrossRef
8.
go back to reference Ryan CG, Grant PM, Tigbe WW, Granat MH (2006) The validity and reliability of a novel activity monitor as a measure of walking. Br J Sports Med 40:779–784PubMedCrossRef Ryan CG, Grant PM, Tigbe WW, Granat MH (2006) The validity and reliability of a novel activity monitor as a measure of walking. Br J Sports Med 40:779–784PubMedCrossRef
9.
go back to reference Maddocks M, Petrou A, Skipper L, Wilcock A (2010) Validity of three accelerometers during treadmill walking and motor vehicle travel. Br J Sports Med 44:606–608PubMedCrossRef Maddocks M, Petrou A, Skipper L, Wilcock A (2010) Validity of three accelerometers during treadmill walking and motor vehicle travel. Br J Sports Med 44:606–608PubMedCrossRef
10.
go back to reference Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5:649–655PubMedCrossRef Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5:649–655PubMedCrossRef
11.
go back to reference Dupont WD, Plummer WD (1990) Power and sample size calculations: a review and computer program. Controlled Clinical Trials 11:116–128PubMedCrossRef Dupont WD, Plummer WD (1990) Power and sample size calculations: a review and computer program. Controlled Clinical Trials 11:116–128PubMedCrossRef
12.
go back to reference Tudor-Locke C, Washington TL, Hart TL (2009) Expected values for steps/day in special populations. Prevent Med 49:3–11CrossRef Tudor-Locke C, Washington TL, Hart TL (2009) Expected values for steps/day in special populations. Prevent Med 49:3–11CrossRef
13.
go back to reference Dahele M, Fearon KCH, Preston T, Skipworth RJE, Voss A, Wall L (2007) Objective physical activity and self-reported quality of life in patients receiving palliative chemotherapy. J Pain Symptom Manage 33:676–685PubMedCrossRef Dahele M, Fearon KCH, Preston T, Skipworth RJE, Voss A, Wall L (2007) Objective physical activity and self-reported quality of life in patients receiving palliative chemotherapy. J Pain Symptom Manage 33:676–685PubMedCrossRef
14.
go back to reference Dajczam E, Kasymjanova G, Kreisman H, Swinton N, Pepe C, Small D (2008) Should patient-rated performance status affect treatment decisions in advanced lung cancer? J Thorac Oncol 3:1133–1136CrossRef Dajczam E, Kasymjanova G, Kreisman H, Swinton N, Pepe C, Small D (2008) Should patient-rated performance status affect treatment decisions in advanced lung cancer? J Thorac Oncol 3:1133–1136CrossRef
Metadata
Title
Exploring physical activity level in patients with thoracic cancer: implications for use as an outcome measure
Authors
Matthew Maddocks
Andrew Wilcock
Publication date
01-05-2012
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 5/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1393-z

Other articles of this Issue 5/2012

Supportive Care in Cancer 5/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine